Anvaya Ventures invests in Accel backed Spyne.ai…… Capillary Revives IPO Plans......Innovaccer closes 275Mn in Series F........ Innovaccer acquires Humbi AI....... Series E at $3.2 Bn valuation........ Surgical Innovation Associates acquired by Integra........Capillary Buys Persuade, Brierley........THB raises $20 Mn.........Ecosoul raises $10 Million

Innovaccer acquires Humbi AI, its 3rd acquisition in a year, to launch actuarial copilots

Innovaccer acquires Humbi AI, its 3rd acquisition in a year, to launch actuarial copilots

Healthcare technology company Innovaccer announced its acquisition of Humbi AI, an actuarial software, services and analytics company used by providers, payers and life sciences companies.

Innovaccer’s cloud powers a slew of healthcare AI features like an AI-assisted care management system, contract management, ambient documentation, pre-visit summary and AI-suggested differential diagnoses.

Financial details of the deal were not disclosed.

The Humbi AI acquisition will help build out Innovaccer’s data analytics capabilities. The Nashville, Tennessee-based company combines healthcare data analytics and actuarial consulting to help healthcare organizations improve value-based contracts, manage risk and design benefits.

Humbi AI’s actuarial capabilities will be an integral component of Innovaccer’s cloud platform, and the company plans to launch its own actuarial copilot, executives said in a press release.

“At Humbi AI, we believe actuarial intelligence is the key to turning complex healthcare data into strategic action,” Puneet Budhiraja, founder and CEO at Humbi AI, said in a statement. “By joining Innovaccer, we are amplifying our ability to help organizations navigate their most critical decisions with actuarial expertise and advanced analytics.”

Humbi’s trove of Medicare and Medicaid data will propel Innovaccer’s healthcare intelligence cloud. Moreover, its technology will aid in creating data-driven, value-based care contracts for providers, according to the company.

For payers, the solution will increase contract performance, payer benchmarking and provider network optimization. For life sciences, the actuarial tool will aid in drug commercialization, clinical effectiveness analysis and utilization metrics.

The company raised its series F financing in early January, at a staggering $275 million. It will use the investment to expand its collaboration with existing customers, introduce new AI and cloud capabilities and scale a developer ecosystem on the platform, executives said.

Share this post